What does microdosing mean in the context of injectable multi-ester blends like Mix-Med?

Microdosing means dividing your total weekly dose into multiple small injections — typically daily or every other day — rather than one or two larger shots. With Mix-Med 225mg/ml, a 0.25–0.33ml draw per injection spreads active compound delivery across the week, keeping plasma androgen levels more stable and reducing the hormonal peaks and troughs common in conventional injection schedules.

What are the practical benefits of running low, continuous doses instead of larger weekly injections?

Low, continuous dosing narrows the peak-to-trough amplitude in serum androgen concentration, which clinical andrology data links to reduced oestrogen fluctuation and more consistent anabolic signalling. Users commonly report easier side-effect management, steadier mood and energy, and more predictable body-composition responses when plasma levels remain near-flat compared to high-oscillation weekly protocols.

Who is a microdosing protocol with Mix-Med 225mg/ml best suited for?

Microdosing protocols are best suited for intermediate users who are oestrogen-sensitive, those managing a performance-support block alongside structured training, and athletes transitioning between cycle phases who need hormonal continuity without abrupt concentration spikes. The 10ml vial format provides sufficient volume for a four-to-five week daily or EOD schedule without frequent reordering.

How do I draw an accurate microdose from a 10ml multi-dose vial using an insulin syringe?

Use a 1ml insulin syringe with a 27–29G needle for drawing small volumes from the vial. At 225mg/ml, 0.33ml equals approximately 74mg of blend. Wipe the rubber stopper with an alcohol swab before each draw, inject air equal to your draw volume to equalise pressure, and aspirate slowly to avoid air bubbles that distort volume accuracy.

How should Mix-Med 225mg/ml be stored after the vial is first opened?

After the first puncture, store the vial upright at room temperature (15–25°C), away from direct light and heat. Refrigeration is not required but is acceptable; if refrigerated, allow the oil to reach room temperature before drawing to maintain solution viscosity and injection comfort. Discard any remaining contents 28 days after first use in line with multi-dose vial sterility conventions. (2) angle_used

Expert Recommendation

Bioniche Pharma

Mix-Med 225mg/ml 10ml Vial by Bioniche Pharma

Name: Mix-Med
Brand: Bioniche Pharma
SKU: INJ-MIX-BNI-225-016
Price: 54.00 EUR
Availability: InStock

Mix-Med 225mg/ml is a multi-ester injectable blend formulated at 225mg/ml in a 10ml vial, purpose-built for athletes who prioritise low, steady-dose microdosing protocols over conventional high-volume cycling. Frequent small injections spread across the week allow precise hormonal calibration while reducing the peak-trough amplitude typical of standard weekly dosing. Every batch of Mix-Med undergoes finished-product HPLC potency verification and LAL endotoxin screening before release — quality controls executed at the compounding stage, not delegated to supplier documentation alone.

€54.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Near-flat plasma androgen curve achieved through frequent sub-threshold injections
225mg/ml concentration enables meaningful per-draw volume even at 0.25–0.33ml doses
Multi-ester ester overlap sustains active compound presence across daily injection windows
Reduced oestrogen fluctuation linked to narrower hormonal peak-trough amplitude
10ml vial volume accommodates a complete four-to-five week microdose block
HPLC-confirmed label accuracy supports reliable milligram-per-draw calculations
LAL-tested batches confirm endotoxin control critical for frequent injection safety

Phase	Dosage	Frequency	Note
Introductory Microdose (Weeks 1–2)	0.25ml per injection / ~56mg per draw	Daily (7x/week)	Establish injection routine and assess individual response at low exposure
Maintenance Microdose (Weeks 3–8)	0.33ml per injection / ~74mg per draw	Daily or EOD (5–7x/week)	Target weekly total 370–520mg; adjust frequency to personal tolerance
Taper / Transition Phase (Weeks 9–10)	0.20ml per injection / ~45mg per draw	EOD (3–4x/week)	Gradually reduce weekly exposure ahead of PCT initiation

Key takeaways

Divide weekly totals into daily or EOD draws for stable plasma levels.
Calculate each draw precisely: 0.33ml delivers roughly 74mg at 225mg/ml.
Use a 23–25G needle to minimise discomfort on frequent injection days.
Verify per-draw accuracy using HPLC-confirmed label potency data.
Discard opened vials after 28 days to maintain aseptic integrity.

Microdosing Defined: What Mix-Med 225mg/ml Delivers in Small, Frequent Doses

Mix-Med 225mg/ml is a multi-ester injectable blend engineered to support microdosing protocols, where the weekly total dose is divided into multiple sub-threshold administrations to sustain near-flat plasma androgen levels throughout the cycle. This approach contrasts with conventional twice-weekly injections by reducing the peak-to-trough hormone swing to its practical minimum. Bioniche Pharma formulates Mix-Med at 225mg/ml — a concentration that allows meaningful per-dose volume even when drawing as little as 0.25–0.33ml per injection.

Why Plasma Stability Matters in a Microdosing Context

Frequent, low-volume injections deliver a predictable benefit: smaller androgenic oscillations translate to more consistent nitrogen retention and reduced oestrogen fluctuation compared to less-frequent, higher-volume protocols. Research published in clinical andrology literature consistently shows that smaller injection intervals narrow the intra-individual coefficient of variation in serum testosterone — a principle directly applicable to multi-ester performance blends. Mix-Med's ester composition provides an overlapping release window that complements daily or every-other-day injection scheduling, so no single ester's trough dominates the pharmacokinetic curve.

Who Benefits Most from Low-Dose Continuous Protocols

Microdosing protocols suit intermediate users managing oestrogen sensitivity, individuals using performance-support compounds alongside structured training blocks, and those transitioning between cycle phases who need hormonal stability without abrupt spikes. Compared to high single-dose weekly injections, daily 0.25–0.33ml draws from a 10ml multi-dose vial using a 23–25G needle minimise injection volume per site while maintaining weekly totals between 315mg and 450mg — a range consistent with moderate-cycle literature benchmarks.

Practical Volume Mathematics

At 225mg/ml, a 0.33ml draw yields approximately 74mg of active blend per injection. Five injections per week delivers roughly 370mg total — achievable within a single 10ml vial across a four-to-five week microdose block. Bioniche Pharma's HPLC-verified label accuracy ensures that per-draw milligram calculations remain reliable across all draw points in the vial.

Usage

Confirm your planned weekly total and divide by injection frequency (daily or EOD) to determine the exact per-draw volume in millilitres before you open the vial.
Wipe the vial stopper with a fresh 70% isopropyl alcohol swab and allow it to dry fully — a critical step when puncturing the same vial repeatedly across a multi-week microdose block.
Draw air into your syringe equal to your dose volume, inject that air into the vial to equalise internal pressure, then aspirate your measured dose slowly to eliminate bubbles.
Rotate injection sites systematically — glutes, quads, delts — so that no single site receives more than two injections per week given the high injection frequency of daily protocols.
Allow refrigerated oil to reach room temperature (15–25°C) before injecting to preserve solution viscosity and reduce injection discomfort.
Log each injection date, site, volume, and any local reaction in a training diary; consistent records allow accurate pharmacokinetic tracking and inform dose adjustments mid-block.

Warnings

Contraindications: Not suitable for individuals with prostate or breast carcinoma, severe hepatic impairment, uncontrolled polycythaemia, or hypersensitivity to any component of the oil-based formulation. Women of childbearing potential should avoid androgenic injectable blends entirely.

Side Effects: Frequent injections increase cumulative androgenic exposure; monitor for acne, scalp sensitivity, and libido changes as early indicators of excess androgen load. Oestrogen-related effects including water retention remain possible despite microdose frequency benefits. Injection-site reactions are typically mild with correct rotation.

Monitoring: Obtain baseline serum haematocrit, haemoglobin, liver enzymes, and lipid panel before initiating. Recheck at week four and at cycle end. Blood pressure should be self-monitored weekly given the androgen-driven cardiovascular load of multi-week protocols.

PCT: PCT timing depends on ester composition and the final injection date. Initiate post-cycle therapy only after sufficient ester clearance; consult a qualified healthcare professional to determine the appropriate SERM protocol and duration based on individual suppression markers.

Frequently asked questions

What does microdosing mean in the context of injectable multi-ester blends like Mix-Med?: Microdosing means dividing your total weekly dose into multiple small injections — typically daily or every other day — rather than one or two larger shots. With Mix-Med 225mg/ml, a 0.25–0.33ml draw per injection spreads active compound delivery across the week, keeping plasma androgen levels more stable and reducing the hormonal peaks and troughs common in conventional injection schedules.
What are the practical benefits of running low, continuous doses instead of larger weekly injections?: Low, continuous dosing narrows the peak-to-trough amplitude in serum androgen concentration, which clinical andrology data links to reduced oestrogen fluctuation and more consistent anabolic signalling. Users commonly report easier side-effect management, steadier mood and energy, and more predictable body-composition responses when plasma levels remain near-flat compared to high-oscillation weekly protocols.
Who is a microdosing protocol with Mix-Med 225mg/ml best suited for?: Microdosing protocols are best suited for intermediate users who are oestrogen-sensitive, those managing a performance-support block alongside structured training, and athletes transitioning between cycle phases who need hormonal continuity without abrupt concentration spikes. The 10ml vial format provides sufficient volume for a four-to-five week daily or EOD schedule without frequent reordering.
How do I draw an accurate microdose from a 10ml multi-dose vial using an insulin syringe?: Use a 1ml insulin syringe with a 27–29G needle for drawing small volumes from the vial. At 225mg/ml, 0.33ml equals approximately 74mg of blend. Wipe the rubber stopper with an alcohol swab before each draw, inject air equal to your draw volume to equalise pressure, and aspirate slowly to avoid air bubbles that distort volume accuracy.
How should Mix-Med 225mg/ml be stored after the vial is first opened?: After the first puncture, store the vial upright at room temperature (15–25°C), away from direct light and heat. Refrigeration is not required but is acceptable; if refrigerated, allow the oil to reach room temperature before drawing to maintain solution viscosity and injection comfort. Discard any remaining contents 28 days after first use in line with multi-dose vial sterility conventions. (2) angle_used

Manufacturer

Sterility architecture sits at the centre of Bioniche Pharma's production philosophy for Mix-Med 225mg/ml: aseptic compounding conditions, validated sterilising filtration, and closed-system filling are applied as non-negotiable manufacturing standards rather than optional quality additions. Each finished batch is subject to LAL endotoxin testing — the limulus amebocyte lysate assay that quantifies bacterial endotoxin load in injectable solutions — alongside HPLC-based potency confirmation performed on the final product rather than on the incoming API alone. This dual-stage release criterion, combining microbiological safety data with chromatographic label-claim verification, reflects a production framework where analytical evidence is generated at the point of patient risk, not at the point of raw material receipt.

Product details

Brand	Bioniche Pharma
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, Mix-Med, Bioniche Pharma Steroid-Mix
Strength	225 mg
Form	Vial
Pack size	1 piece
Item number	INJ-MIX-BNI-225-016

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Hardcore Cutting

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Best Value

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00